Abstract
N-5' was given orally to 21 patients with perennial type nasal allergy for 4 weeks continuously.
Subjective and objective improvement was noted in 85.7%, moderate or better in 47.6%.
The good effects of this drug appeared within 1 week in 33.2%, and within 2 weeks in 72.2% or earlier than with most drugs.
Sneezing, nasal discharge and nasal obstruction (the major symptoms of nasal allergy) were significantly reduced in 80.0%, 76.2% and 73.3% of the patients, respectively.
Gastric discomfort was noted in 1 case, but this was not severe enough to require discontinuation of the medication.
The evaluation of N-5' by the attending physicians, including relative effetiveness and absence of side effects, showed 85.7% usefulness, which is higher than the rating for most drugs. Therefore, we consider that N-5' is a new antiallergic drug which can be recommended for the treatment of perennial type nasal allergy.
